Help your patients find FREEDOM with the power of two
Introducing the FREEDOM-1 and FREEDOM-2 clinical trials
For your patients who either:
- Will receive a kidney transplant from a living kidney donor (FREEDOM-1)
OR
- Have already received a kidney transplant from a living kidney donor within the last 3 to 12 months (FREEDOM-2)
The FREEDOM clinical trials
The FREEDOM-1 (phase 3) and FREEDOM-2 (phase 2) trials are evaluating the safety and efficacy of an investigational cell therapy called FCR001 in living donor kidney transplant recipients and safety in kidney donors.
What is the purpose of these trials?
The FREEDOM trials will help us assess the safety and efficacy of an investigational cell therapy called FCR001.
Who can participate?
We are looking for people who recently had a kidney transplant or are planning on receiving one from a living donor soon.
How long are these trials?
All recipients—in both trials—will have regular study visits for about five years.
Take the next step for your patient
Thank you for taking the time to learn more about the FREEDOM-1 and FREEDOM-2 clinical trials.
